MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/atm-20-4960

Медицинская библиотека · Annals of translational medicine · 2021

An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients.

Sun Feng, Kou Hao, Wang Shengfeng, Lu Yun, Zhao Houyu, Li Wenjing, Zhou Qingxin, Jiang Qiaoli, Cheng Yinchu, Yang Kun, Zhuo Lin, Xu Yang, Wu Dongfang, Zhan Siyan, Cheng Hong

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The coronavirus disease 2019 (COVID-19) epidemic has lasted for nearly 4 months by this study was conducted. We aimed to describe drug utilization, disease progression, and adverse drug events of COVID-19.

METHODS

A retrospective, single-center case series study enrolled 165 consecutive hospitalized COVID-19 patients who were followed up until March 25, 2020, from a designated hospital in Wuhan. Patients were grouped by a baseline degree of severity: non-severe and severe. An analytical study of drug utilization, disease progression, and adverse events (AEs) of COVID-19 was conducted.

RESULTS

Of the 165 COVID-19 cases, antivirals, antibacterials, glucocorticoids, and traditional Chinese medicine (TCM) were administered to 92.7%, 98.8%, 68.5%, and 55.2% of patients, respectively. The total kinds of drugs administered to the severe subgroup [26, interquartile range (IQR) 18-39] were 11 more than the non-severe subgroup (15, IQR 10-24), regardless of comorbidities. The 2 most common combinations of medications in the 165 cases were 'antiviral therapy + glucocorticoids + TCM' (81, 49.1%) and 'antiviral therapy + glucocorticoids' (23, 13.9%). Compared with non-severe cases, severe cases received more glucocorticoids (88.5% vs. 66.2%, P=0.02), but less TCM (50.0% vs. 63.3%, P=0.20), and suffered a higher percentage of death (34.6% vs. 7.2%, P=0.001). At the end of the follow-up, 130 (78.8%) patients had been discharged, and 24 (14.5%) died. There were 13 patients (7.9%) who had elevated liver enzymes, and 49 patients (29.7%) presented with worsening kidney function during the follow-up.

CONCLUSIONS

Of the 165 COVID-19 patients, the fatality rate remained high (14.5%). Drug utilization for COVID-19 was diverse and generally complied with the existing guidelines. Combination regimens containing antiviral drugs might be beneficial to assist COVID-19 recovery. Additionally, liver and kidney AEs should not be ignored.

Для цитирования: Sun Feng, Kou Hao, Wang Shengfeng, Lu Yun, Zhao Houyu, Li Wenjing, Zhou Qingxin, Jiang Qiaoli, Cheng Yinchu, Yang Kun, Zhuo Lin, Xu Yang, Wu Dongfang, Zhan Siyan, Cheng Hong. An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients.. Annals of translational medicine. 2021. DOI: 10.21037/atm-20-4960.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.